Article
FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Aug 2007
Zhang Wu, Gordon Michael, Schultheis Anne M, Yang Dong Yun, Nagashima Fumio, Azuma Mizutomo, Chang Heung-Moon, Borucka Eva, Lurje Georg, Sherrod Andy E, Iqbal Syma, Groshen Susan, Lenz Heinz-Josef
Abstract excerpt
PURPOSE: Cetuximab, a chimeric immunoglobulin G 1 (IgG1) anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb), has shown efficacy in 10% of patients with metastatic colorectal cancer (CRC). Recent studies demonstrate antibody-dependent cell-mediated cytotoxicity (ADCC) is one of the modes of action for rituximab and trastuzumab. Fragment c (Fc) portion of IgG1 mAb has shown to induce ADCC....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.